Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes

被引:5
|
作者
Zhang, Jie [1 ]
Deng, Yuanyuan [1 ]
Wan, Yang [1 ]
Wang, Jiao [1 ,2 ,3 ]
Xu, Jixiong [1 ,2 ,3 ]
机构
[1] Nanchang Univ, Dept Endocrinol & Metab, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China
[2] Jiangxi Clin Res Ctr Endocrine & Metab Dis, Nanchang, Jiangxi, Peoples R China
[3] Jiangxi Branch Natl Clin Res Ctr Metab Dis, Nanchang, Jiangxi, Peoples R China
来源
关键词
diabetes; classification of diabetes; cluster analysis; diabetes therapy; duration of diabetes; ASSOCIATION; SUBGROUPS; MELLITUS; CHINESE; RISK;
D O I
10.3389/fendo.2022.994836
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThis study aimed to cluster patients with diabetes and explore the association between duration of diabetes and diabetes treatment choices in each cluster. MethodsA Two-Step cluster analysis was performed on 1332 Chinese patients with diabetes based on six parameters (glutamate decarboxylase antibodies, age at disease onset, body mass index, glycosylated hemoglobin, homeostatic model assessment 2 to estimate beta-cell function and insulin resistance). Associations between the duration of diabetes and diabetes treatment choices in each cluster of patients were analyzed using Kaplan-Meier survival curves and logistic regression models. ResultsThe following five replicable clusters were identified: severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), and mild age-related diabetes (MARD). There were significant differences in blood pressure, blood lipids, and diabetes-related complications among the clusters (all P < 0.05). Early in the course of disease (<= 5 years), compared with the other subgroups, the SIRD, MOD, and MARD populations were more likely to receive non-insulin hypoglycemic agents for glycemic control. Among the non-insulin hypoglycemic drug options, SIRD had higher rates of receiving metformin, alpha-glucosidase inhibitor (AGI), and glucagon-like peptide-1 drug; the MOD and MARD groups both received metformin, AGI and sodium-glucose cotransporter 2 inhibitor (SGLT-2i) drug ratio was higher. While the SAID and SIDD groups were more inclined to receive insulin therapy than the other subgroups, with SAID being more pronounced. With prolonged disease course (>5 years), only the MOD group was able to accept non-insulin hypoglycemic drugs to control the blood sugar levels, and most of them are still treated with metformin, AGI, and SGLT-2i drugs. While the other four groups required insulin therapy, with SIDD being the most pronounced. ConclusionsClustering of patients with diabetes with a data-driven approach yields consistent results. Each diabetes cluster has significantly different disease characteristics and risk of diabetes complications. With the development of the disease course, each cluster receives different hypoglycemic treatments.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Clinical Characterization of Data-Driven Diabetes Clusters of Pediatric Type 2 Diabetes
    Abbasi, Mahsan
    Tosur, Mustafa
    Astudillo, Marcela
    Refaey, Ahmad
    Sabharwal, Ashutosh
    Redondo, Maria J.
    [J]. PEDIATRIC DIABETES, 2023, 2023
  • [2] Utility of data-driven clusters for the prevention of type 2 diabetes
    Yacaman-Mendez, D.
    Zhou, M.
    de Leon, A. Ponce
    Ebbevi, D.
    Lager, A.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2020, 30
  • [3] Glycemic Response To Initial Treatment In Data-driven Diabetes Clusters In A Real-world Sample Of Adults With Newly Diagnosed Diabetes
    Raghavan, Sridharan
    Liu, Wenhui
    Warsavage, Theodore
    Phillips, Lawrence
    Reusch, Jane E.
    Caplan, Liron
    [J]. CIRCULATION, 2022, 145
  • [4] Characterization of data-driven clusters in diabetes-free adults and their utility for risk stratification of type 2 diabetes
    Mendez, Diego Yacaman
    Zhou, Minhao
    Lagerros, Ylva Trolle
    Velasco, Donaji V. Gomez
    Tynelius, Per
    Gudjonsdottir, Hrafnhildur
    de Leon, Antonio Ponce
    Eeg-Olofsson, Katarina
    Ostenson, Claes-Goran
    Brynedal, Boel
    Aguilar Salinas, Carlos A.
    Ebbevi, David
    Lager, Anton
    [J]. BMC MEDICINE, 2022, 20 (01)
  • [5] Characterization of data-driven clusters in diabetes-free adults and their utility for risk stratification of type 2 diabetes
    Diego Yacamán Méndez
    Minhao Zhou
    Ylva Trolle Lagerros
    Donaji V. Gómez Velasco
    Per Tynelius
    Hrafnhildur Gudjonsdottir
    Antonio Ponce de Leon
    Katarina Eeg-Olofsson
    Claes-Göran Östenson
    Boel Brynedal
    Carlos A. Aguilar Salinas
    David Ebbevi
    Anton Lager
    [J]. BMC Medicine, 20
  • [6] The Diabetes Lifemap: Data-Driven Diabetes Care for the 21st Century
    Kolade, Victor O.
    [J]. FAMILY MEDICINE, 2022, 54 (01) : 64 - 65
  • [7] Data-driven type 2 diabetes patient clusters predict metabolic surgery outcomes
    Flannick, Jason
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (03): : 150 - 151
  • [8] Data-driven classification of health status of older adults with diabetes: The diabetes and aging study
    Huang, Elbert S.
    Liu, Jennifer Y.
    Lipska, Kasia J.
    Grant, Richard W.
    Laiteerapong, Neda
    Moffet, Howard H.
    Schumm, L. Philip
    Karter, Andrew J.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 (07) : 2120 - 2130
  • [9] Chinese diabetes datasets for data-driven machine learning
    Zhao, Qinpei
    Zhu, Jinhao
    Shen, Xuan
    Lin, Chuwen
    Zhang, Yinjia
    Liang, Yuxiang
    Cao, Baige
    Li, Jiangfeng
    Liu, Xiang
    Rao, Weixiong
    Wang, Congrong
    [J]. SCIENTIFIC DATA, 2023, 10 (01)
  • [10] Data-driven policies needed to turn the tide on diabetes
    Dain, Katie
    [J]. LANCET, 2020, 396 (10267): : 1948 - 1949